Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR10842349

—

9494e843-7766-501c-9e43-ddce363ab1a1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ALLOGRAFT_REJECTION+0.600
  • IL6_JAK_STAT3_SIGNALING+0.600
  • INTERFERON_GAMMA_RESPONSE+0.600
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.500
  • INFLAMMATORY_RESPONSE+0.500
  • INTERFERON_ALPHA_RESPONSE+0.500
  • TNFA_SIGNALING_VIA_NFKB+0.500
  • COMPLEMENT+0.400
  • IL2_STAT5_SIGNALING+0.400
  • ANGIOGENESIS+0.300

Top 10 suppressed

  • MYC_TARGETS_V1-0.500
  • MYC_TARGETS_V2-0.500
  • OXIDATIVE_PHOSPHORYLATION-0.500
  • PROTEIN_SECRETION-0.400
  • DNA_REPAIR-0.300
  • E2F_TARGETS-0.300
  • FATTY_ACID_METABOLISM-0.300
  • MTORC1_SIGNALING-0.300
  • ADIPOGENESIS-0.200
  • SPERMATOGENESIS-0.200

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1TCGA-OR-A5JO-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.911
2SRR2779183
melanoma-umap@29
——0.909
3MDT-AP-1168
medullo-epn-umap@date-based
MedMedulloblastoma0.909
4MDT-AP-1128
medullo-epn-umap@date-based
MedMedulloblastoma0.908
5SRR5088910
melanoma-umap@29
——0.901
6SRR5088860
melanoma-umap@29
——0.895
7TCGA-L9-A743-01A-43R-A39D-07
lung-landscapes@6
—cohortA10.894
86bf9821d-da67-470f-9650-69d05b056166
melanoma-umap@29
——0.890
9BS_Z28VKGNS
brain-umap@2
Neurofibroma—0.889
10MDT-AP-0390
medullo-epn-umap@date-based
MedMedulloblastoma0.889

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 29 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ALLOGRAFT_REJECTION0.600Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.600Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.600Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.500Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.500Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.500Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.500Inavolisib— uncovered
COMPLEMENT0.400Inavolisib— uncovered
IL2_STAT5_SIGNALING0.400Idelalisib— uncovered
ANGIOGENESIS0.300Remibrutinib— uncovered
APICAL_JUNCTION0.300Inavolisib— uncovered
APOPTOSIS0.300Idelalisib— uncovered
KRAS_SIGNALING_UP0.300Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.300Inavolisib— uncovered
COAGULATION0.200Binimetinib— uncovered
HYPOXIA0.200Idelalisib— uncovered
NOTCH_SIGNALING0.200Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.200Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
UV_RESPONSE_DN0.200Inavolisib— uncovered